Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analyst Predicts $20bn COVID Vaccines Market In 2021

Pfizer Expected To Take Early Lead

Executive Summary

Analysts have taken a first stab at predicting the size of the COVID-19 vaccine market – in which Pfizer and Moderna are likely to start strong, but could give way to other big players.

You may also be interested in...



Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race

Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.

4D Pharma Is Latest Biotech Casualty After Creditor Calls Time

The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.

Novartis To Cut 8,000 Jobs In Global Restructure

CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC142804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel